CY1109117T1 - Διαμορφωσεις enaιωphmatoς, οι οποιες περιλαμβανουν δραστικον συστατικο, επιφανειακως δρωσαν ουσια poloxamer ή meroxapol και γλυκολη, χρησις του δια την βιομηχανικην παρασκευην φαρμακου προς νοσηλειαν οφθαλμικων διαταραχων - Google Patents
Διαμορφωσεις enaιωphmatoς, οι οποιες περιλαμβανουν δραστικον συστατικο, επιφανειακως δρωσαν ουσια poloxamer ή meroxapol και γλυκολη, χρησις του δια την βιομηχανικην παρασκευην φαρμακου προς νοσηλειαν οφθαλμικων διαταραχωνInfo
- Publication number
- CY1109117T1 CY1109117T1 CY20091100579T CY091100579T CY1109117T1 CY 1109117 T1 CY1109117 T1 CY 1109117T1 CY 20091100579 T CY20091100579 T CY 20091100579T CY 091100579 T CY091100579 T CY 091100579T CY 1109117 T1 CY1109117 T1 CY 1109117T1
- Authority
- CY
- Cyprus
- Prior art keywords
- poloxamer
- meroxapol
- epifaneiakos
- enaiophmatos
- chrisis
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 title abstract 2
- 229960000502 poloxamer Drugs 0.000 title abstract 2
- 229920001983 poloxamer Polymers 0.000 title abstract 2
- 239000004480 active ingredient Substances 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 229940079593 drug Drugs 0.000 title 1
- 150000002334 glycols Chemical class 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 abstract 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 abstract 2
- 239000007900 aqueous suspension Substances 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 abstract 1
- 229940023490 ophthalmic product Drugs 0.000 abstract 1
- 239000004094 surface-active agent Substances 0.000 abstract 1
- 230000000699 topical effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US67933205P | 2005-05-10 | 2005-05-10 | |
| EP06759258A EP1885336B1 (en) | 2005-05-10 | 2006-05-08 | Suspension formulations comprising an active principle, a poloxamer or meroxapol surfactant and a glycol, its use for the manufacture of a medicament for treating ophthalmic disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1109117T1 true CY1109117T1 (el) | 2014-07-02 |
Family
ID=37081695
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20091100579T CY1109117T1 (el) | 2005-05-10 | 2009-05-29 | Διαμορφωσεις enaιωphmatoς, οι οποιες περιλαμβανουν δραστικον συστατικο, επιφανειακως δρωσαν ουσια poloxamer ή meroxapol και γλυκολη, χρησις του δια την βιομηχανικην παρασκευην φαρμακου προς νοσηλειαν οφθαλμικων διαταραχων |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20060257487A1 (enExample) |
| EP (1) | EP1885336B1 (enExample) |
| JP (1) | JP4968954B2 (enExample) |
| KR (1) | KR20080011310A (enExample) |
| CN (1) | CN101175475B (enExample) |
| AT (1) | ATE428401T1 (enExample) |
| AU (1) | AU2006244244B2 (enExample) |
| BR (1) | BRPI0609227A2 (enExample) |
| CA (1) | CA2607608A1 (enExample) |
| CY (1) | CY1109117T1 (enExample) |
| DE (1) | DE602006006308D1 (enExample) |
| DK (1) | DK1885336T3 (enExample) |
| ES (1) | ES2322200T3 (enExample) |
| MX (1) | MX2007014083A (enExample) |
| PL (1) | PL1885336T3 (enExample) |
| PT (1) | PT1885336E (enExample) |
| SI (1) | SI1885336T1 (enExample) |
| WO (1) | WO2006121963A2 (enExample) |
| ZA (1) | ZA200709251B (enExample) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2006244245B2 (en) * | 2005-05-10 | 2010-11-18 | Alcon, Inc. | Ophthalmic suspension comprising an ophthalmic drug, a poloxamine and a glycol tonicity-adjusting agent, use of said composition for the manufacture of a medicament for treating ophthalmic disorders |
| US20100130580A1 (en) * | 2006-01-25 | 2010-05-27 | Aciex Therapeutics, Inc. | Formulations and Methods for Treating Dry Eye |
| US20070254841A1 (en) * | 2006-01-25 | 2007-11-01 | Ophthalmic Research Associates, Inc. | Formulations and methods for treating dry eye |
| TW200812575A (en) * | 2006-04-28 | 2008-03-16 | Alcon Inc | Formulations containing amide derivatives of carboxylic acid NSAIDs for topical administration to the eye |
| US20090105245A1 (en) * | 2006-12-21 | 2009-04-23 | Bingaman David P | Methods for treating macular edema and ocular angiogenesis using an anti-inflammatory agent and a receptor tyrosine kinase inhibitor |
| CN101754748A (zh) * | 2007-05-24 | 2010-06-23 | 阿西克斯医疗公司 | 治疗干眼症的制剂和方法 |
| TW201023912A (en) * | 2008-12-05 | 2010-07-01 | Alcon Res Ltd | Pharmaceutical suspension |
| CN105362221A (zh) * | 2009-03-03 | 2016-03-02 | 爱尔康研究有限公司 | 向眼部递送受体酪氨酸激酶抑制性(RTKi)化合物的药物组合物 |
| US8912236B2 (en) * | 2009-03-03 | 2014-12-16 | Alcon Research, Ltd. | Pharmaceutical composition for delivery of receptor tyrosine kinase inhibiting (RTKi) compounds to the eye |
| WO2010103120A1 (en) * | 2009-03-12 | 2010-09-16 | Medichem, S.A. | New crystals of a benzoylbenzeneacetamide derivative |
| HUE038821T2 (hu) * | 2009-12-03 | 2018-11-28 | Novartis Ag | Karboxivinil polimert tartalmazó nanorészecske szuszpenziók |
| EA201400064A1 (ru) | 2011-06-28 | 2014-05-30 | Байер Хелфкеэ Ллк | Офтальмологическая фармацевтическая композиция для местного применения, которая содержит регорафениб |
| CA2840491A1 (en) | 2011-06-28 | 2013-01-03 | Bayer Healthcare Llc | Topical ophthalmological pharmaceutical composition containing sorafenib |
| US20130065888A1 (en) | 2011-08-15 | 2013-03-14 | Biserka Cetina-Cizmek | Ophthalmic formulations and processes for their preparation |
| GR1007906B (el) * | 2012-03-22 | 2013-05-30 | Φαρματεν Αβεε, | Οφθαλμικο φαρμακευτικο σκευασμα περιεχον ενα αναστολεα καρβονικης ανυδρασης και μεθοδος για την παρασκευη αυτου |
| US9056057B2 (en) | 2012-05-03 | 2015-06-16 | Kala Pharmaceuticals, Inc. | Nanocrystals, compositions, and methods that aid particle transport in mucus |
| US11596599B2 (en) | 2012-05-03 | 2023-03-07 | The Johns Hopkins University | Compositions and methods for ophthalmic and/or other applications |
| WO2013166408A1 (en) | 2012-05-03 | 2013-11-07 | Kala Pharmaceuticals, Inc. | Pharmaceutical nanoparticles showing improved mucosal transport |
| US9827191B2 (en) | 2012-05-03 | 2017-11-28 | The Johns Hopkins University | Compositions and methods for ophthalmic and/or other applications |
| CN104582685A (zh) | 2012-06-25 | 2015-04-29 | 拜尔健康护理有限责任公司 | 含有舒尼替尼的局部眼科药物组合物 |
| UY35183A (es) | 2012-12-21 | 2014-07-31 | Bayer Healthcare Llc | Composición farmacéutica oftalmológica tópica que contiene regorafenib |
| US9353122B2 (en) | 2013-02-15 | 2016-05-31 | Kala Pharmaceuticals, Inc. | Therapeutic compounds and uses thereof |
| US9688688B2 (en) | 2013-02-20 | 2017-06-27 | Kala Pharmaceuticals, Inc. | Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof |
| US9353123B2 (en) | 2013-02-20 | 2016-05-31 | Kala Pharmaceuticals, Inc. | Therapeutic compounds and uses thereof |
| WO2014160579A1 (en) * | 2013-03-25 | 2014-10-02 | Insite Vision Incorporated | Combination anti-inflammatory ophthalmic compositions |
| WO2014207769A1 (en) | 2013-06-27 | 2014-12-31 | Mylan Laboratories Ltd | Process for the preparation of nepafenac |
| US20160279055A1 (en) | 2013-07-22 | 2016-09-29 | Imprimis Pharmaceuticals, Inc. | Pharmaceutical ophthalmic compositions for intraocular administration and methods for fabricating thereof |
| US20150164882A1 (en) | 2013-07-22 | 2015-06-18 | Imprimis Pharmaceuticals, Inc. | Pharmaceutical compositions for intraocular administration and methods for fabricating thereof |
| CA2919081C (en) * | 2013-07-22 | 2021-11-16 | Imprimis Pharmaceuticals, Inc. | Pharmaceutical compositions for intraocular administration comprising an antibacterial agent and an antiinflammatory agent |
| KR20160099084A (ko) | 2013-11-01 | 2016-08-19 | 칼라 파마슈티컬스, 인크. | 치료 화합물의 결정질 형태 및 그의 용도 |
| US9890173B2 (en) | 2013-11-01 | 2018-02-13 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
| CN104706579A (zh) * | 2015-03-12 | 2015-06-17 | 广州仁恒医药科技有限公司 | 一种夫西地酸滴眼液及其制备方法 |
| SI3288379T1 (sl) | 2015-05-01 | 2022-06-30 | Onl Therapeutics, Inc. | Peptidne sestave in načini uporabe |
| US10253036B2 (en) | 2016-09-08 | 2019-04-09 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
| WO2018048750A1 (en) | 2016-09-08 | 2018-03-15 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
| EP3509421A4 (en) | 2016-09-08 | 2020-05-20 | Kala Pharmaceuticals, Inc. | CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF |
| US12102622B2 (en) | 2021-02-10 | 2024-10-01 | Iolyx Therapeutics, Inc. | Methods for ophthalmic delivery of roflumilast |
| KR102356603B1 (ko) * | 2021-08-05 | 2022-02-08 | 지엘팜텍주식회사 | 안구건조증 치료를 위한 레코플라본 함유 점안 조성물 |
| US12263160B2 (en) | 2021-09-22 | 2025-04-01 | Iolyx Therapeutics, Inc. | Methods of treating ocular inflammatory diseases |
| CN114272207B (zh) * | 2022-01-21 | 2023-04-11 | 山东诺明康药物研究院有限公司 | 一种纳米晶混悬滴眼液及其制备方法 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4313949A (en) * | 1979-09-26 | 1982-02-02 | A. H. Robins Company, Inc. | Method of producing an inhibitory effect on blood platelet aggregation |
| US4910225A (en) * | 1988-01-27 | 1990-03-20 | Senju Pharmaceutical Co., Ltd. | Locally administrable therapeutic composition for inflammatory disease |
| US5521222A (en) * | 1989-09-28 | 1996-05-28 | Alcon Laboratories, Inc. | Topical ophthalmic pharmaceutical vehicles |
| US5461081A (en) * | 1989-09-28 | 1995-10-24 | Alcon Laboratories, Inc. | Topical ophthalmic pharmaceutical vehicles |
| US5369095A (en) * | 1990-02-14 | 1994-11-29 | Alcon Laboratories, Inc. | Compositions and method comprising substituted glycosides as mucus membrane permeation enhancers |
| IT1252692B (it) * | 1991-11-27 | 1995-06-23 | Zambon Spa | Composizione farmaceutica per uso oftalmico contenente un antiinfiammatorio non steroideo ed un decongestionante come principi attivi |
| EP0551626A1 (en) * | 1991-12-19 | 1993-07-21 | LEK, tovarna farmacevtskih in kemicnih izdelkov, d.d. | Thermoreversible gel as a liquid pharmaceutical carrier for a galenic formulation |
| US5364884A (en) * | 1993-01-21 | 1994-11-15 | Baylor College Of Medicine | Arginine compounds as ocular hypotensive agents |
| US5631005A (en) * | 1994-09-21 | 1997-05-20 | Alcon Laboratories, Inc. | Use of amidoamines in ophthalmic compositions |
| US5631004A (en) * | 1993-09-30 | 1997-05-20 | Alcon Laboratories, Inc. | Use of sustained release antibiotic compositions in ophthalmic surgical procedures |
| US5540930A (en) * | 1993-10-25 | 1996-07-30 | Pharmos Corporation | Suspension of loteprednol etabonate for ear, eye, or nose treatment |
| US5475034A (en) * | 1994-06-06 | 1995-12-12 | Alcon Laboratories, Inc. | Topically administrable compositions containing 3-benzoylphenylacetic acid derivatives for treatment of ophthalmic inflammatory disorders |
| JPH10158188A (ja) * | 1996-11-29 | 1998-06-16 | Senju Pharmaceut Co Ltd | 角膜治療用組成物 |
| US6265444B1 (en) * | 1997-05-23 | 2001-07-24 | Insite Vision Incorporated | Ophthalmic composition |
| BR9806123A (pt) * | 1997-07-29 | 1999-08-31 | Alcon Lab Inc | Soluções condicionantes para cuidado de lente de contato dura |
| US6037328A (en) * | 1998-12-22 | 2000-03-14 | Bausch & Lomb Incorporated | Method and composition for rewetting and preventing deposits on contact lens |
| US6582724B2 (en) * | 1999-12-16 | 2003-06-24 | Dermatrends, Inc. | Dual enhancer composition for topical and transdermal drug delivery |
| EP1249249A1 (en) * | 2000-12-12 | 2002-10-16 | Menicon Co., Ltd. | Ophthalmic composition |
| AR030346A1 (es) * | 2000-08-14 | 2003-08-20 | Alcon Inc | Metodo de tratamiento de desordenes neurodegenerativos de la retina y cabeza de nervio optico |
| AR031135A1 (es) * | 2000-10-10 | 2003-09-10 | Upjohn Co | Composiciones de antibiotico topico para el tratamiento de infecciones oculares |
| JP2002332225A (ja) * | 2001-05-09 | 2002-11-22 | Lion Corp | 眼科用組成物 |
| EP1441696B1 (en) * | 2001-11-01 | 2010-05-19 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Method and composition for dry eye treatment |
| JP2003176228A (ja) * | 2001-12-11 | 2003-06-24 | Rohto Pharmaceut Co Ltd | 液 剤 |
| US20030133905A1 (en) * | 2001-12-20 | 2003-07-17 | Zhenze Hu | Composition for treating contact lenses in the eye |
| US6765001B2 (en) * | 2001-12-21 | 2004-07-20 | Medicis Pharmaceutical Corporation | Compositions and methods for enhancing corticosteroid delivery |
| US7119112B2 (en) * | 2002-02-28 | 2006-10-10 | Icagen, Inc. | Sulfonamides as potassium channel blockers |
| AU2003217810C9 (en) * | 2002-02-28 | 2008-06-12 | Icagen, Inc. | Methods for treating diseases related to intraocular pressure |
| US20040115270A1 (en) * | 2002-12-13 | 2004-06-17 | Dharmendra Jani | Absorption and controlled release of polyethers from hydrogel biomaterials |
| TWI358290B (en) * | 2004-12-02 | 2012-02-21 | Alcon Inc | Topical nepafenac formulations |
| AU2006244245B2 (en) * | 2005-05-10 | 2010-11-18 | Alcon, Inc. | Ophthalmic suspension comprising an ophthalmic drug, a poloxamine and a glycol tonicity-adjusting agent, use of said composition for the manufacture of a medicament for treating ophthalmic disorders |
-
2006
- 2006-05-08 SI SI200630323T patent/SI1885336T1/sl unknown
- 2006-05-08 DE DE602006006308T patent/DE602006006308D1/de not_active Expired - Lifetime
- 2006-05-08 KR KR1020077027974A patent/KR20080011310A/ko not_active Ceased
- 2006-05-08 DK DK06759258T patent/DK1885336T3/da active
- 2006-05-08 AU AU2006244244A patent/AU2006244244B2/en not_active Ceased
- 2006-05-08 US US11/430,239 patent/US20060257487A1/en not_active Abandoned
- 2006-05-08 EP EP06759258A patent/EP1885336B1/en not_active Expired - Lifetime
- 2006-05-08 ES ES06759258T patent/ES2322200T3/es not_active Expired - Lifetime
- 2006-05-08 ZA ZA200709251A patent/ZA200709251B/xx unknown
- 2006-05-08 JP JP2008511214A patent/JP4968954B2/ja not_active Expired - Fee Related
- 2006-05-08 CA CA002607608A patent/CA2607608A1/en not_active Abandoned
- 2006-05-08 BR BRPI0609227-6A patent/BRPI0609227A2/pt not_active IP Right Cessation
- 2006-05-08 WO PCT/US2006/017606 patent/WO2006121963A2/en not_active Ceased
- 2006-05-08 PL PL06759258T patent/PL1885336T3/pl unknown
- 2006-05-08 PT PT06759258T patent/PT1885336E/pt unknown
- 2006-05-08 MX MX2007014083A patent/MX2007014083A/es active IP Right Grant
- 2006-05-08 AT AT06759258T patent/ATE428401T1/de active
- 2006-05-08 CN CN2006800161308A patent/CN101175475B/zh not_active Expired - Fee Related
-
2009
- 2009-05-29 CY CY20091100579T patent/CY1109117T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SI1885336T1 (sl) | 2009-08-31 |
| MX2007014083A (es) | 2008-02-07 |
| CA2607608A1 (en) | 2006-11-16 |
| KR20080011310A (ko) | 2008-02-01 |
| AU2006244244B2 (en) | 2010-11-04 |
| ATE428401T1 (de) | 2009-05-15 |
| AU2006244244A1 (en) | 2006-11-16 |
| DK1885336T3 (da) | 2009-05-25 |
| WO2006121963A3 (en) | 2007-03-22 |
| PT1885336E (pt) | 2009-05-07 |
| PL1885336T3 (pl) | 2009-08-31 |
| JP2008540532A (ja) | 2008-11-20 |
| ES2322200T3 (es) | 2009-06-17 |
| DE602006006308D1 (de) | 2009-05-28 |
| EP1885336A2 (en) | 2008-02-13 |
| US20060257487A1 (en) | 2006-11-16 |
| JP4968954B2 (ja) | 2012-07-04 |
| CN101175475B (zh) | 2010-04-14 |
| ZA200709251B (en) | 2009-08-26 |
| WO2006121963A2 (en) | 2006-11-16 |
| BRPI0609227A2 (pt) | 2010-03-09 |
| EP1885336B1 (en) | 2009-04-15 |
| CN101175475A (zh) | 2008-05-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200709251B (en) | Suspension formulations comprising an active principle, a poloxamer or meroxapol surfactant and a glycol, its use for the manufacture of a medicament for treating ophthalmic disorders | |
| CY1108676T1 (el) | Οφθαλμικο εναιωρημα περιλαμβανον ενα οφθαλμικο φαρμακο, μια πολοξαμινη και εναν παραγοντα ρυθμισεως της τονικοτητας τυπου γλυκολης, χρηση της εν λογω συνθεσεως για την παραγωγη ενος φαρμακου για την αγωγη οφθαλμικων διαταραχων | |
| UY29562A1 (es) | Compuestos heterocíclicos de amino benzoilo, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciones | |
| BRPI0509863A (pt) | liberação de fármaco para fundo de olho | |
| UY29561A1 (es) | Derivados de quinazolina, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciones | |
| PA8548401A1 (es) | Agentes antibacterianos | |
| CY1120462T1 (el) | Τοπικες ανθελμινθικες κτηνιατρικες τυποποιησεις | |
| BR112015029512A2 (pt) | derivados de pirazolopirrolidina e seu uso no tratamento de doenças | |
| UY29633A1 (es) | Derivados de oxindol | |
| NO20040547L (no) | Amino-ftalazinonderivater aktive som kinaseinhibitorer, fremgangsmate for deres fremstilling og farmasoytiske sammensetninger inneholdende disse. | |
| DE602004017194D1 (de) | Pyridylpyrrol-derivate als wirksame kinase-hemmer | |
| NO20041086L (no) | Aminoindazolderivatrer aktive som kinaseinhibitorer, fremgangsmater for deres fremstilling og farmasoytiske sammensetninger som inneholder dem | |
| CY1114803T1 (el) | Παραγωγα πυριμιδινο σουλφοναμιδιου ως ρυθμιστες υποδοχεων χημειοκινης | |
| NO20081844L (no) | Terapeutiske forbindelser | |
| UY30460A1 (es) | Compuestos terapéuticos | |
| NO20082088L (no) | Azetidiner som MEK-inhibitorer for behandling av proliferative sykdommer | |
| MX390044B (es) | Derivados de naftiridinona y su uso en el tratamiento de la arritmia. | |
| UY27275A1 (es) | Composiciones y metodos para aumentar la biodisponibilidad de agentes farmacéuticos | |
| CO2022006066A2 (es) | Agente terapéutico y agente profiláctico para trastornos gastrointestinales funcionales y xerostomía | |
| UY30847A1 (es) | Uso de derivados de mononitrato de dianhidrohexita como agentes para el tratamiento de trastornos intestinales | |
| EP1608395A4 (en) | ANTICROPE WITH LK8 PROTEIN AS AN ACTIVE SUBSTANCE | |
| DK1814848T3 (da) | 2,3,4-substitueret-cyclopentanoner som terapeutiske midler | |
| WO2007077203A3 (en) | Triterpenequinone and triterpenephenol derivatives and their application for the treatment of tumors and parasitic diseases | |
| BRPI0515344A (pt) | composto, composição farmacêutica, e, usos de uma quantidade eficaz de um composto 3-fosfoindol ou sal, pró-droga, estereoisÈmero, tautÈmero, n-óxido ou amina quaternária farmaceuticamente aceitável do mesmo e de uma quantidade de tratamento eficaz anti-hiv de um composto de 3-fosfoindol ou sal, pró-droga, estereo-isÈmero, tautÈmero, n-óxido ou amina quaternária farmaceuticamente aceitável do mesmo | |
| PA8546201A1 (es) | Agentes antibacterianos |